The article presents a clinical case of a patient with recurrent implantation failure (RIF) of embryos using assisted reproductive technologies (ART). The relevance of the problem is underscored by the fact that RIF occurs in 10% of couples undergoing infertility treatment with ART. In this clinical case, embryo testing for aneuploidy and correction of uterine and endometrial pathology were performed. An isolated circulation of low-titer anti-beta2-glycoprotein 1 antibodies was detected, which did not meet the international criteria for antiphospholipid syndrome (APS). However, after consulting with a hematologist and a rheumatologist, it was decided to conduct prophylactic therapy using low doses of acetylsalicylic acid and low molecular weight heparins. This regimen is recognized as the first-line therapy for obstetric APS and allows to obtain live births in 80—85% of patients. This case illustrates the importance of a multifactorial approach to the diagnosis and treatment of RIF, considering both chromosomal and immunological factors. The experience shows that an individualized treatment approach, taking into account all factors of implantation failure, increases the chances of a successful pregnancy in patients with RIF.